Rositsa Dacheva
Rositsa is a rheumatologist in Sofia, Bulgaria. Her interests include inflammatory arthritis, systemic lupus erythematosus, interstitial lung disease, systemic sclerosis and musculoskeletal ultrasound. Rositsa is a member of the Newsletter Sub-Committee. Rositsa is a Country Liaison for Bulgaria.
| Oral 0007 | Wednesday 12.06.2024 4:30-4:40 PM Abstracts: Clinical trials and other treatment aspects in Rheumatoid arthritis Author: Prof. Emery, P. (Leeds, United Kingdom) Title: Subcutaneous Abatacept vs. Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from the Phase 3 AMPLIFIED trial  This randomized, phase 3 study evaluated the clinical profile of dual seropositivity, SE+, and MTX-IR in patients with early RA and assessed if they could predict a superior response to ABA-compared with ADA, both on background MTX. |
| Poster 0017 | Wednesday 12.06.2024 3:42-3:48 PM Clinical Poster Tours: Rheumatoid Arthritis I Author: Atiqi, S. (Netherlands) Title: Successful Therapeutic Drug Monitoring Based Adalimumab Dose Reduction in Rheumatoid Arthritis Patient with Low Disease Activity (ADDORA-LOW): A Single Blind, Non-Inferiority, Randomized Clinical Trial Therapeutic drug monitoring-based strategy targeting a drug level of 2mg/L is non-inferior to a target level of 5 mg/L with respect to disease activity and number of flares. |
| Oral 0020 | Wednesday 12.06.2024 4:40-4:50 PM Clinical Abstract Sessions: Clinical trials and other treatment aspects in Rheumatoid arthritis Author: Winthrop, K. (USA) Title: Immunogenecity of an Adjuvant Recombinant Zoster Vaccine in patients with Rheumatoid Arthritis Treated with Upadacitinib: 60-week Results form a Randomized Substudy This study evaluated the long-term immunogenicity of recombinant zoster vaccine in patients with RA receiving UPA 15 mg QD with background MTX. Satisfactory humoral and cell-mediated responses were achieved by most patients at wks 4, 16 and 60 with no serious AEs reported. |
| Oral 0092 | Wednesday 12.06.2024 05:30-05:40 PM Clinical Abstract Sessions: Clinical trials and other treatment aspects in Rheumatoid arthritis Author: Aymon, R. (Switzerland) Title: Infections in Patients with Rheumatoid Arthritis Treated with JAK-Inhibitors Compared to bDMARDs: Findings form an International Collaboration of Registers (The JAK-POT Study) The study recruited 54,905 patients form 14 RA registers and assessed the incidence of infections and HZ in RA patients treated with JAKi, compared to other biologic agents. There was no significantly higher risk of infections in patients treated with JAKi compared to TNFi. The incidence of HZ was significantly higher in patients receiving JAKi. |
| Poster 0069 | Thursday 13.06.2024 09:36-09:42 AM Clinical Poster Tours: Management of RMDs in the ”Global South” Author: Ziade, N. (Lebanon) Title: Global Disparities in the Treatment of Rheumatoid Arthritis in Different Regions of the World: Analysis of Results from the International COVAD-2 Study The objectives of the study were to assess worldwide disparities in different DMARDs, with a focus on novel therapies, in patients with RA from the COVAD2 study. |